CoronaryAtlas logo
CoronaryAtlas
antithrombin III
Pathway / Coagulation & thrombus formation

antithrombin III

SERPINC1protein

Antithrombin III is consumed during thrombin-driven thrombus formation, and its depletion indicates active coagulation in acute infarction.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencemedium
RationaleCoagulation inhibitor; depleted during thrombosis; consumed in AMI thrombus formation.
Druggability
DruggableYes
Known drugs / candidates12
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000117601

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
53
A — assay feasibility
84
E — evidence strength
86
T1DI (composite)
22
Specificity differential (R−C)-38.3
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 0
3hypovolemia / dehydrationmag 2
4tachyarrhythmian/a
5hypoxemia / respiratory failuremag 2
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 2
Coverage: 5/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 13 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Platelet-poor plasma
Collection tube
Sodium citrate 3.2% (light blue-top)
Method / principle
Chromogenic anti-Xa or anti-IIa activity
Reagent / substrate
Factor Xa/IIa excess + chromogenic substrate; heparin cofactor
Platform
Coagulation analyzer
Turnaround · availability
Routine–send-out · Clinical

Human genetic evidence

0.603
Open Targets association (myocardial_infarction)

Literature evidence(17)